Last 22 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.08 | — | — | — | 0.04 | 0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | 1.79 | — | 0.06 | 0.02 | 0.17 | 0.10 | 0.09 | 11079.73 | — | 28215.68 | 6558.13 | 3891.22 | 34319.87 | 77827.55 | 46246.97 | 14862.53 |
| — | — | — | — | — | +983.2% | — | -32.5% | -100.0% | — | -100.0% | -100.0% | +184.7% | — | -63.7% | -85.8% | -73.8% | -45.1% | -1.0% | — | — | |
| P/B Ratio | 0.00 | 0.03 | 0.06 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 726.19 | 852.25 | 742.78 | 664.85 | 607.86 | 1002.38 | 2204.65 | 3021.86 | 1754.97 |
| — | +1489.9% | +1236.4% | +46.9% | +240.4% | +47.1% | +273.7% | +56.6% | -100.0% | -100.0% | -100.0% | -100.0% | +19.5% | -15.0% | -66.3% | -78.0% | -65.4% | -56.1% | +15.0% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | -0.09 | — | — | -0.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 100.0% | — | — | 78.8% | 60.9% | -755.6% | 64.7% | 35.0% | 114.2% | — | 26.2% | 64.7% | 64.7% | 52.4% | 58.2% | 52.2% | 52.3% |
| — | — | — | — | +64.3% | — | — | +125.4% | -46.7% | — | +146.7% | -46.0% | +76.5% | — | -54.9% | +23.8% | +23.6% | +110.9% | -26.5% | — | — | |
| Operating Margin | — | — | — | — | 863.2% | -66300.0% | — | -937.9% | -715.2% | -15477.8% | -4641.2% | -2051.2% | -2019.2% | — | -2295.4% | -1440.9% | -637.9% | -3450.6% | -4108.5% | -1535.6% | -802.6% |
| — | — | — | — | +220.7% | -328.4% | — | +54.3% | +64.6% | — | -102.2% | -42.4% | -216.6% | — | +44.1% | +6.2% | +20.5% | -90.5% | -37.8% | — | — | |
| Net Margin | — | — | — | — | -1866.2% | 21450.0% | — | -1807.6% | -976.9% | -23888.9% | -4505.9% | -1755.8% | -1638.2% | — | -1938.1% | -1416.1% | -622.0% | -3434.1% | -4043.3% | -1517.5% | -823.9% |
| — | — | — | — | -91.0% | +189.8% | — | -3.0% | +40.4% | — | -132.5% | -24.0% | -163.4% | — | +52.1% | +6.7% | +24.5% | -90.4% | -48.5% | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.4% | 36.8% | -152.2% | -46.0% | 10.4% | 6.0% | -97.5% | -28.8% | -27.8% | -38.4% | -13.2% | -13.5% | -31.3% | -46.5% | -13.7% | -32.6% | -21.9% | -30.9% | -25.8% | -22.6% | -21.9% |
| — | +510.2% | -56.1% | -59.6% | +137.4% | +115.7% | -637.4% | -113.7% | +11.2% | +17.3% | +3.7% | +58.6% | -43.2% | -50.6% | +46.7% | -44.4% | +0.2% | -100.7% | -55.1% | — | — | |
| ROA | -31.0% | 29.4% | -63.5% | -35.8% | 8.1% | 4.6% | -59.7% | -18.6% | -24.3% | -32.3% | -11.1% | -12.3% | -27.7% | -41.4% | -12.2% | -28.6% | -19.4% | -26.5% | -20.9% | -18.7% | -19.0% |
| — | +543.9% | -6.5% | -92.3% | +133.2% | +114.1% | -435.2% | -51.4% | +12.3% | +22.0% | +8.6% | +57.1% | -43.1% | -56.4% | +41.7% | -53.1% | -2.2% | -96.8% | -45.1% | — | — | |
| ROIC | -41.6% | -11.8% | -66.1% | -56.4% | -5.3% | -29.0% | -87.4% | -22.6% | -30.7% | -40.7% | -24.7% | — | -68.0% | -81.1% | -44.9% | -754.6% | -404.8% | -557.4% | — | — | — |
| — | +59.4% | +24.4% | -149.9% | +82.8% | +28.8% | -254.6% | — | +54.8% | +49.8% | +45.1% | — | +83.2% | +85.5% | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.01 | 0.24 | 0.04 | 0.06 | 0.13 | 0.13 | 0.21 | 0.00 | 0.00 | 0.21 | 0.00 | 0.01 | — | 0.00 | 0.01 | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 |
| — | -91.7% | +83.0% | -82.9% | +4019.1% | +26212.5% | -36.3% | +11543.8% | -79.3% | — | +10921.9% | -64.5% | -60.2% | — | -89.7% | -74.4% | -14.1% | +564.6% | +1244.6% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.19 | 3.90 | 3.72 | 4.73 | 4.19 | 4.21 | 4.73 | 4.44 | 3.82 | 6.52 | 3.43 | 7.89 | 7.02 | 4.49 | 6.70 | 7.86 | 8.77 | 11.32 | 6.45 | 6.28 | 7.76 |
| — | -7.2% | -21.4% | +6.4% | +9.9% | -35.4% | +37.8% | -43.7% | -45.6% | +45.1% | -48.8% | +0.4% | -20.0% | -60.3% | +3.9% | +25.2% | +13.0% | +13.7% | -23.4% | — | — | |
| Quick Ratio | 4.19 | 3.90 | 3.72 | 4.73 | 4.19 | 4.20 | 4.72 | 4.43 | 3.79 | 6.42 | 3.37 | 7.70 | 6.86 | 4.35 | 6.55 | 7.72 | 8.66 | 11.19 | 6.40 | 6.25 | 7.74 |
| — | -7.1% | -21.2% | +6.8% | +10.6% | -34.6% | +40.1% | -42.5% | -44.8% | +47.6% | -48.6% | -0.3% | -20.7% | -61.1% | +2.3% | +23.6% | +11.9% | +12.6% | -23.9% | — | — | |
| Interest Coverage | -30.69 | — | -4.27 | -73.47 | — | — | -2.78 | -0.86 | -26.68 | -33.98 | -9.99 | — | -150.95 | — | — | — | — | -1325.22 | — | -999999.00 | -178.45 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 22 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NXTS stock.
Nexentis Technologies Inc.'s current P/E is -0.1x. The average P/E over the last 1 quarters is 0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Nexentis Technologies Inc.'s business trajectory between earnings reports.